Aligos Therapeutics Presses Capital Raise Button
Aligos Therapeutics Inc (NASDAQ:ALGS) commenced an underwritten public offering of 4 million shares of common stock. Underwriters can purchase up to…
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 28)
22 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
Exela Technologies, Inc. (NASDAQ: XELA) rose 39% to $2.05 in pre-market trading after gaining over 5% on Monday.
Aligos Therapeutics To Present Phase 1 Safety, Pharmacokinetic Data for STOPS Molecule Drug Candidate ALG-010133 And Several Nonclinical Chronic Hepatitis B Programs At Digital International Liver Congress 2021
Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that a poster
Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
-Five scientific posters to be presented at upcoming EASL ILC meeting
- All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being evaluated in
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell
• Revlon (NYSE:REV) is likely to report earnings for its first quarter.
• Bluegreen Vacations (NYSE:BVH) is expected to report earnings for its first quarter.
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.